PFD Highlights Regeneration Biomedical’s Presentation at ISCT 2026 Annual Meeting
PFD Capital Partners announced that portfolio company Regeneration Biomedical, Inc. presented newly reported clinical findings at the ISCT 2026 Annual Meeting in Dublin, Ireland, highlighting its direct-to-brain regenerative therapy platform for Alzheimer’s disease and other neurodegenerative conditions. The release focuses on completed Phase I findings showing reductions and normalization trends in Alzheimer’s-related biomarkers, including CSF […]
PFD Capital Partners Announces That Regeneration Biomedical Has Applied For Phase IIa Clinical Trial
PFD Capital Partners announced that Regeneration Biomedical, Inc. (RBI) has submitted FDA data from its Phase I Alzheimer’s trial and is seeking approval for a multi-center Phase IIa study. This first-in-human trial of direct brain injections of autologous, Wnt-activated stem cells demonstrated safety and early efficacy signals, including measurable improvements in cognition and biomarkers not […]
Stanley Otake Named Lead Consultant For Medical Receivables Acquisition, Diligence, and Portfolio Servicing
PFD Capital Partners has appointed Stanley Otake as Lead Consultant for Medical Receivables Acquisition, Diligence, and Portfolio Servicing & Collections. With more than 40 years of senior executive experience in healthcare, Otake brings extensive expertise in hospital operations, distressed and bankrupt facility management, and medical receivables valuation. His background spans hospitals, sub-acute facilities, surgery centers, […]
PFD Has Completed Relocation To Its New Irvine Headquarters.
PFD Capital Partners, Inc. (PFD) has finished its relocation to their brand new headquarters in Irvine, CA. PFD, announced several months ago its intention to move from its original Lake Forest location as the company’s growth and client servicing could no longer be met at the old facility. This milestone reflects PFD’s consistent growth, unwavering […]
RBI’s President and Founder Presents Breakthrough Stem Cell Therapy For CNS Disorders.
At the 2024 ISCT Annual Meeting, Dr. Christopher Duma of Regeneration Biomedical, Inc. (RBI) presented encouraging early data from a first-in-human trial of its CEREWiNT™ stem cell platform for Alzheimer’s and related diseases. The therapy delivers Wnt-activated autologous stem cells directly into the brain, aiming to regenerate rather than just manage symptoms. Preliminary results show […]
PFD Announces Regeneration Biomedical As A Portfolio Company In Upcoming Hybrid Medical Receivables Fund
Announced today by Robert Pryke, PFD Capital Partners LLC, Director and Fund Manager for PFD Special Medical Receivables Hybrid (SMH) 3002, that Regeneration Biomedical, Inc. (RBI)—a clinical-stage biotechnology company advancing stem cell-based therapies for neurodegenerative diseases—will be included in its upcoming PFDSMH3002.
PFDSelect Medical Receivables 1013, LLC Has Officially Closed To New Investors
Gary L. Ermoian, COO & Co-founder, today announced PFDSelect Medical Receivables 1013, LLC has officially closed to new investors. The manager informed the capital team that the offering reached its maximum investor allocation as of Tuesday, May 20, 2025.
PFD/iOI Launches “iKnee” Comfort Study: A Major Milestone in Orthopedic Innovation
PFD Capital Partners, Inc., Closes on Purchase of Regeneration Biomedical, Inc., Series A Preferred Stock
Lake Forest, CA – Danette Roascio-Leonard, Co-founder and VP Operations of PFD Capital Partners, Inc., is pleased to announce that the company has successfully closed on and purchased 84,938 shares of Regeneration Biomedical, Inc. (RBI) Series A Preferred Stock.
2024 NKC Milestone Progress Update
Announced today by Robert Pryke, PFD Capital Partners LLC, Director and Fund Manager for PFD Management Opportunity Fund 3001 LLC: Significant developments in the HuygensTM Catheter project are under way. Timeline for 2024 is detailed in the attached report from Neuro-Kinesis Corporation (NKC).